Pharmacotherapy efficacy and safety criteria based on spectral shifts in elder patients with arterial hypertension and coronary artery disease by Shtanko, V. A. et al.
 325 
Shtanko V. A., Tofan N. V., Khyzhnyak O. V., Yablonska V. B., Novikov S. A. Pharmacotherapy efficacy and safety criteria based 
on spectral shifts in elder patients with arterial hypertension and coronary artery disease. Journal of Education, Health and Sport. 
2017;7(11):325-333. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.1158692 
http://ojs.ukw.edu.pl/index.php/johs/article/view/5219 
 
 
 
 
The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017). 
1223 Journal of Education, Health and Sport eISSN 2391-8306 7 
© The Authors 2017; 
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland 
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, 
provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial 
use, distribution and reproduction in any medium, provided the work is properly cited. 
The authors declare that there is no conflict of interests regarding the publication of this paper. 
Received: 06.11.2017. Revised: 20.11.2017. Accepted: 30.11.2017. 
 
PHARMACOTHERAPY EFFICACY AND SAFETY CRITERIA BASED ON 
SPECTRAL SHIFTS IN ELDER PATIENTS WITH ARTERIAL HYPERTENSION 
AND CORONARY ARTERY DISEASE 
  
V. A. Shtanko, N. V. Tofan, O. V. Khyzhnyak, V. B. Yablonska, S. A. Novikov  
 
Odessa National Medical University 
Internal medicine department №2 
 
Abstract  
The article is dedicated to development of homeostatic criteria of efficacy and safety 
of drugs combinations “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic 
acid”. These criteria are based on study of homeostatic shifts and their association with 
clinical and laboratory parameters on elder patients with arterial hypertension (AH) II, III 
stage combined with coronary artery disease (CAD).  
Complex clinical, biochemical, biophysical and instrumental investigation was 
performed in 67 patients with AH II, III stage combined with CAD.  
On the grounds of developed criteria was established that for patients with AH II and 
CAD is not recommended combination “lisinopril, acetylsalicylic acid” and for those ones 
with AH III and CAD prohibited combinations “lisinopril, bisoprolol, acetylsalicylic acid” 
and “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid” in order to 
prevent development of drug induced renal dysfunction.  
It was also determined safety of combinations “lisinopril, bisoprolol, acetylsalicylic 
acid”; “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for patients with AH II and 
CAD and “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for those ones with AH III 
and CAD.  
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Introduction 
Arterial hypertension (AH) and coronary artery disease (CAD) prevail among all 
cardio-vascular diseases namely in elder patients – 41.8% and 38.3%. This comorbidity 
increases risk of mortality and complications: myocardial infarction, stroke, heart failure [1].  
Choice of effective and safe pharmacotherapy (PT) is not easy because of different 
comorbid diseases in these patients and peculiarities of pharmacokinetics and 
pharmacodynamics. Elder patients have retardation of absorption and spreading of drugs, 
decrease of their biotransformation pace, slow elimination [2]. These patients have more often 
complications after PT, untypical reactions, frequent hemodynamic disorders [3]. 
Low treatment efficacy and high risk of complications caused by PT is a reason to 
seek for informative methods of diagnostics and evaluation of treatment influence in elderly. 
Laboratory methods which allow hold polysystemic estimation of homeostatic state and take 
into consideration intermolecular interactions in the blood components are able to decide this 
challenge [4]. 
One of such methods is laser correlation spectroscopy (LCS) [5]. This method allows 
reveal such blood components as proteins, which transport drugs and low density lipoproteins, 
which take part in atherogenesis process. And it is wide known that one of the theories of AH 
and CAD development is presence of atherosclerotic changes in coronary arteries, aorta and 
its branches [6]. But its possibilities in prognosis of side effects during treatment and 
evaluation of PT influence on homeostatic shifts are not studied and investigated enough in 
elder patients with cardiac comorbidity.  
So, the investigation object was to study homeostatic criteria of efficacy and safety on 
the background of different antihypertensive combinations influence and their association 
with traditional clinic and biochemical data in elderly with AH II, III stages combined with 
CAD.  
 
Material and methods 
107 patients with PH II, III stages combined with CAD  were examined and treated in 
therapeutic department of Centre of reconstructive and restorative medicine (University 
Clinic). Their mean age was 70.8±7.5 years. Diagnosis was based on clinical, laboratory and 
instrumental data according to ESH/ESC recommendations [7]. Besides obligatory 
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investigation methods vegetative index Kerdo (VIK) was calculated in the investigation by 
formula [8]:  
VIK = 1-(d/p)*100, where d – is diastolic blood pressure (DBP) and p – heart rate 
(HR) in one minute. Glomerular filtration rate (GFR) was also calculated according to MDRD 
formula [9]. 
All patients were divided into 2 groups: group I (n=51) – those ones with AH II stage 
and CAD, group II (n=57) – patients with AH III stage and CAD.  
Patients of the group I received 3 variants of the combined PT: variant Іа – “lisinopril, 
acetylsalicylic acid” (n=19); Іb – “lisinopril, bisoprolol, acetylsalicylic acid” (n=11); Іс – 
“lisinopril, bisoprolol, indapamide, acetylsalicylic acid” (n=20).  
Patients of the group II were prescribed also 3 variants of the combined PT: variant ІІа 
– “lisinopril, bisoprolol, acetylsalicylic acid” (n=19); ІІb – “lisinopril, bisoprolol, indapamide, 
acetylsalicylic acid” (n=20); ІІс – “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, 
acetylsalicylic acid” (n=17). 
Monitoring during PT was for 14 days of the patients stay in therapeutic department. 
In this period of time all proper laboratory and instrumental investigations were carried out 
and blood serum for LCS was taken.  
The special laboratory method for estimation of serum homeostatic features was LCS. 
It helps to measure spectral characteristics of the induced monochromatic coherent radiation 
in biological liquids. That makes possible to register particles with hydrodynamic radius 1 - 
10000 nanometers. Results are presented as a histogram [5]. 
According to previous studies [10], to the I zone (0-10 nanometers) are included low-
molecular monomeric albumins and glycolipid free complexes; to the II zone (11-30 
nanometers) are included globulin proteins and low-molecular lipoprotein complexes; to the 
III zone (31-70 nanometers) are included high-molecular lipoprotein complexes, RNP-,  DNP 
molecules, the low-molecular immune complexes; to the IV zone (71-150 nanometers) are 
included mainly constitutive immune complexes of the average size. Huge particles (≥ 150 
nanometers, the V zone) are present in patients with allergization. 
Investigation of  blood serum by mean of LCS was made using the technique 
developed by prof. Bazhora Yu.I. and prof. Noskin L.A. [11]. Blood serum was taken on the 
2nd and 14th day of the treatment.  
Obtained results were calculated with statistics parametric and nonparametric 
methods. Data were presented as mediana, 25th and 75th percentile [12].  
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Results 
In the group AH II with CAD prescription of combination “lisinopril, acetylsalicylic 
acid” caused stabilization of systolic blood pressure (SBP) and DBP in target borders 
recommended for elderly (below 150/90 mm Hg) and HR on the 2nd day of PT. This 
combination led to growth of creatinine level by 18.0 mcmol/l and decrease of GFR by 22.2 
ml/min/1,73m2 on the 10th day of treatment (р<0,05). So, combination “lisinopril, 
acetylsalicylic acid” causes development of drug induced renal dysfunction.   
Under the influence of combination “lisinopril, bisoprolol, acetylsalicylic acid” SBP 
reached recommended rates on the 1st day of treatment, while vegetative nervous regulation 
(VNR) was shifted towards  direction of pathological parasympatheticotonia (VIK = -42.8 
units). Such a dynamic of VNR can be connected with neuromodulatory action of bisoprolol.  
Combination “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” caused lowering 
of SBP and DBP to target levels on the 2nd day of PT. VNR in this group was normally 
directed – physiological parasympatheticotonia. 
Data on subfractional redistribution in blood serum and directions of spectral shifts 
under the influence of combinations Іа, Іb, Іс in the group I presented in tables 1 and 2.   
 
Table 1 
Dynamic of subfractional redistribution in blood under the influence of combinations Іа, Іb, Іс 
in the group AH II and CAD 
DDZ, 
% 
Used combination of drugs 
Combination Ia Combination Ib Combination Iс 
before PT during PT before PT during PT before PT during PT 
І 
(0-10 nm) 
4 
(1,5; 12,5) 
3 
(0; 10) 
3 
(1; 5) 
7 
(2,5; 11) 
5,5 
(2,7; 9,2) 
3 
(1; 9,5) 
ІІ 
(11-30 nm) 
13 
(7; 31) 
21 
(11; 29) 
17 
(13; 19) 
22 
(14; 30) 
24,5 
(16; 38,2) 
18,5 
(5; 31,5) 
ІІІ 
(31-70 nm) 
25 
(5,5; 47) 
31 
(24; 47) 
24 
(23,5; 43) 
33 
(23,5; 36,5) 
20 
(11; 42) 
18,5 
(0; 30,5) 
IV 
(71-150 nm) 
25 
(11; 51,5) 
25 
(0; 33*) 
22 
(0; 45) 
20 
(7,5; 42,5) 
28,5 
(13,2; 41,5) 
28,5 
(16,2; 66,7*) 
V 
(>150 nm)  
4 
(0; 18,5) 
0 
(0; 2) 
13 
(1; 46) 
8 
(0; 16*) 
6 
(0; 22) 
6 
(0; 25) 
Remark: *- p<0,05 after PT vs before PT; DDZ – discrete dynamic zone; combination Іа: 
“lisinopril, acetylsalicylic acid”; Іb: “lisinopril, bisoprolol, acetylsalicylic acid”; Iс: 
“lisinopril, bisoprolol, indapamide, acetylsalicylic acid”.   
Data presented as mediana; 25th and 75th percentile in the brackets.  
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Table 2 
Directions of spectral shifts under the influence of combinations Іа, Іb, Іс in the group AH II 
and CAD 
Type of homeostatic 
direction, % 
Used combination of drugs 
Іа Іb Іс 
before 
PT 
during 
PT 
before 
PT 
during 
PT 
before 
PT 
during 
PT 
Normological 5,3 15,4 0 9,1 0 6,2 
Hydrolytic 36,8 46,2 27,2 45,4* 40 31,4 
Anabolic 42,1 38,4 54,6 27,3* 45 50 
Mixed 15,8 0* 18,2 18,2 15 12,4 
Remark: *- p<0,05 after PT vs before PT. 
 
Under the influence of studied combinations there were not any statistical changes in 
LCS data of subfractional redistribution. At the same time 75th percentile showed significant 
decrease of particles with diameter 71-150 nm by 18.5% after prescription of combination 
“lisinopril, acetylsalicylic acid”, lowering of particles above 150 nm by 30.0% at the 
background of combination “lisinopril, bisoprolol, acetylsalicylic acid” and growth of 
particles with diameter 71-150 nm after usage of combination “lisinopril, bisoprolol, 
indapamide, acetylsalicylic acid”.  
Dynamic of homeostatic shifts under the influence of combination “lisinopril, 
acetylsalicylic acid” was following: decrease of mixed type by 15.8%. Usage of combination 
“lisinopril, bisoprolol, acetylsalicylic acid” led to growth of hydrolytic type by 18.2% with 
simultaneous lowering of anabolic one by 27.3%. After prescription of combination 
“lisinopril, bisoprolol, indapamide, acetylsalicylic acid” was observed prevalence of anabolic 
type among all other homeostatic spectral shifts.  
Growth of creatinine level under the influence of combination “lisinopril, 
acetylsalicylic acid” was associated with decrease of particles with diameter of 71-150 nm (r 
= -.70). Lowering of VIK rate after prescription of combination “lisinopril, bisoprolol, 
acetylsalicylic acid” correlated with decrease of particles with diameter above 150 nm (r = 
+.52). Decline of SBP rate at the background of combination “lisinopril, bisoprolol, 
indapamide, acetylsalicylic acid” associated with growth of particles with diameter 71-150 
nm (r = -.73).  
In the group AH III with CAD SBP and DBP reached target borders on the 2nd day of 
treatment at the background of combinations “lisinopril, bisoprolol, acetylsalicylic acid” and 
“lisinopril, bisoprolol, indapamide, acetylsalicylic acid”. Combination “lisinopril, bisoprolol, 
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indapamide, isosorbide dinitrate, acetylsalicylic acid” caused stabilization of SBP, DBP and 
HR on recommended rates on the 2nd day of PT. Combination “lisinopril, bisoprolol, 
acetylsalicylic acid” led to shift of VNR towards direction of pathological 
parasympatheticotonia (VIK = -24.0 Units). 
Combinations “lisinopril, bisoprolol, acetylsalicylic acid” and “lisinopril, bisoprolol, 
indapamide, isosorbide dinitrate, acetylsalicylic acid” induced growth of blood creatinine 
level by 22.5 mcmol/l and 31.0 mcmol/l and decrease of GFR by 25.4 ml/min/1,73m2 and 
18.5 ml/min/1,73m2.  
Combinations “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” and “lisinopril, 
bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid” caused appearance of 
microalbuminuria (0.1  g/l). 
Results on subfractional redistribution in blood serum and directions of spectral shifts 
under the influence of combinations ІIа, ІIb, ІIс in the group II presented in tables 3 and 4.   
 
Table 3 
Dynamic of subfractional redistribution in blood under the influence of combinations ІIа, ІIb, 
ІIс in the group AH III and CAD 
DDZ, 
% 
Used combination of drugs 
Combination IIa Combination IIb Combination IIc 
before PT during PT before PT during PT before PT during PT 
І 
(0-10 nm) 
6 
(2,5; 13) 
5 
(2; 11,8) 
7 
(2; 15,8) 
6 
(1,8; 12) 
5 
(1; 17) 
7 
(4; 11,5) 
ІІ 
(11-30 nm) 
16 
(11,5; 48) 
23,5 
(13; 30,8) 
31,5 
(20,8; 41,8) 
14,5* 
(10,3; 34,8) 
24 
(12; 52) 
32 
(11; 39) 
ІІІ 
(31-70 nm) 
24 
(16; 35,5) 
21 
(5,3; 32,3) 
16,5 
(7,3; 28,5) 
17,5 
(0; 29) 
13 
(4; 22) 
27* 
(13,5; 32) 
IV 
(71-150 nm) 
12 
(6,5; 41,5) 
38,5* 
(9,5; 54,3) 
12 
(6,8; 24,3) 
32* 
(11; 43,5) 
17 
(4; 32) 
19 
(10; 42) 
V 
(>150 nm) 
2 
(0; 12,5) 
11,5 
(0; 19,3) 
7 
(0; 30) 
12,5 
(5,5; 32,8) 
7 
(0; 38) 
0 
(0; 15) 
Remark: *- p<0,05 after PT vs before PT; combination ІIа: “lisinopril, bisoprolol, 
acetylsalicylic acid”; Іb: “lisinopril, bisoprolol, indapamide, acetylsalicylic acid”; Iс: 
“lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid”. Data presented 
as mediana; 25th and 75th percentile in the brackets.  
 
 
 
 
 
 331 
Table 4 
Directions of spectral shifts under the influence of combinations Іа, Іb, Іс in the group AH II 
and CAD 
Type of 
homeostatic 
direction, % 
Used combination of drugs 
Іа Ib Іc 
before 
PT 
during 
PT 
before 
PT 
during 
PT 
before 
PT 
during 
PT 
Normological 10,5 11,1 10,0 9,1 0,0 6,3 
Hydrolytic 52,7 27,8* 55,0 45,4 35,4 31,2 
Anabolic 31,5 27,7 20,0 27,3 47,0 50,0 
Mixed 5,3 33,4* 15,0 18,2 17,6 12,5 
Remark: *- p<0,05 after PT vs before PT.      
 
Under the influence of combination “lisinopril, bisoprolol, acetylsalicylic acid” in 
subfractional redistribution was observed increase of particles with diameter of  71-150 nm by 
26.5% according to LCS data. Combination “lisinopril, bisoprolol, indapamide, acetylsalicylic 
acid” caused decrease of particles with diameter 11-30 nm with simultaneous increase of 71-
150 nm particles. Combination “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, 
acetylsalicylic acid” induced growth of particles with diameter of 31-70 nm by 14%.  
Homeostatic shifts after prescription of combination “lisinopril, bisoprolol, 
acetylsalicylic acid” were characterized by increase of mixed type by 28.1% and decrease of 
hydrolytic one by 24.9%. Two other combinations didn’t cause any significant changes in 
direction of spectral shifts.  
Increase of creatinine level under the influence of combination “lisinopril, bisoprolol, 
acetylsalicylic acid” associated with decrease of hydrolytic type of homeostatic shifts (r = -
.53) and growth of mixed one (r = +.62) and at the background of combination “lisinopril, 
bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid” it is correlated with increase 
of particles with diameter of 31-70 nm (r = +.68). Lowering of DBP while prescribing 
combination lisinopril, bisoprolol, indapamide, acetylsalicylic acid” associated with decrease 
of particles with diameter 11-30 nm (r= +.59) and reduce of SBP correlated with growth of 
particles with diameter 71-150 nm (r = -.66). 
 
Conclusions 
Studied by mean of LCS molecular mechanisms and homeostatic shifts in blood serum 
under the influence of different pharmacotherapy combinations allowed develop homeostatic 
criteria of treatment efficacy and safety in elder patients with AH combined with CAD. These 
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criteria correlate with traditional biochemical and hemodynamic parameters.  
Revealed homeostatic shifts which associated with development of drug induced renal 
dysfunction in patients with AH II, III with CAD can be useful for maintaining of PT safety. 
Changes of LCS parameters which associated with renal dysfunction developed before 
increase of creatinine level. That fact can be crucial for PT correction at time.  
According to developed criteria for patients with AH II and CAD is not recommended 
combination “lisinopril, acetylsalicylic acid” and for patients with AH III and CAD – 
combinations “lisinopril, bisoprolol, acetylsalicylic acid” and “lisinopril, bisoprolol, 
indapamide, isosorbide dinitrate, acetylsalicylic acid” in order to prevail drug induced renal 
dysfunction.  
It is also determined safety and efficacy of combinations “lisinopril, bisoprolol, 
acetylsalicylic acid”; “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for patients with 
AH II and CAD and combination “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for 
patients with AH III and CAD.   
Obtained data can be used for choice of optimal pharmacotherapy in elderly with AH 
combined with CAD and prevent progress of treatment side effects. So, LCS can be 
recommended as an informative method of clinical pharmacology for usage in clinical 
practice.  
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